Εμφανίζονται 1 - 20 Αποτελέσματα από 839 για την αναζήτηση '"КОНФЛИКТ ИНТЕРЕСОВ"', χρόνος αναζήτησης: 0,78δλ Περιορισμός αποτελεσμάτων
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Academic Journal

    Πηγή: Economic development and analysis; Vol. 3 No. 10 (2025): Economic Development and Analysis; 209-214 ; Экономическое развитие и анализ; Том 3 № 10 (2025): Экономическое развитие и анализ; 209-214 ; Iqtisodiy taraqqiyot va tahlil; Jild 3 № 10 (2025): Iqtisodiy taraqqiyot va tahlil; 209-214 ; 2992-877X ; 10.60078/2992-877X-2025-vol3-iss10

    Περιγραφή αρχείου: application/pdf

  6. 6
    Academic Journal

    Συνεισφορές: The authors express their sincere gratitude to the staff of the St. Petersburg Population Cancer Registry for their assistance in conducting the study., Авторы выражают искреннюю благодарность сотрудникам Популяционного ракового регистра Санкт-Петербурга за помощь в проведении исследования.

    Πηγή: Epidemiology and Vaccinal Prevention; Том 23, № 6 (2024); 24-33 ; Эпидемиология и Вакцинопрофилактика; Том 23, № 6 (2024); 24-33 ; 2619-0494 ; 2073-3046

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.epidemvac.ru/jour/article/view/2116/1079; Wild C.P., Weiderpass E., Stewart B.W. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer. 2020. Доступно на: http://publications.iarc.fr/586. Ссылка активна на 3 февраля 2024.; Cancer Research UK. In situ cervical carcinoma incidence statistics. 2020. Доступно на: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statisticsby-cancer-type/cervical-cancer/incidence-in-situ#heading-Zero. Ссылка активна на 4 апреля 2024.; Гарелик Т. М., Наумов И. А. Изучение клинико-эпидемиологической ситуации по выявлению рака шейки матки в гродненской области как элемент разработки мер вторичной профилактики // Современные проблемы гигиены, радиационной и экологической медицины. 2017. № 7. С. 33–44.; Каприн А. Д., Старинский В. В., Шахзадова А. О. и др. Злокачественные новообразования в России в 2022 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2023.; Хоров О. Г., Никита Е. И., Плавский Д. М. Евразийский. Дифференциальная диагностика облигатных заболеваний гортани. Евразийский онкологический журнал. 2019. Т. 7, № 3. С. 304–312.; Степанова Ю. Е., Готовяхина Т. В., Корень Е. Е. и др. Эндоскопическая диагностика предопухолевых заболеваний и рака гортани в практике врача-фониатра // Российская оториноларингология. 2017. № 6 (91). С. 128–134.; Markou K., Christoforidou A., Karasmanis I., et al. Laryngeal cancer: epidemiological data from Νorthern Greece and review of the literature // Hippokratia. 2013; Vol. 17, №4. Р. 313–318.; Nelson R.A., Levine A.M., Bernstein L., et al. Changing patterns of anal canal carcinoma in the United States // J Clin Oncol. 2013. Vol. 31, №12. Р. 1569–1575. doi:10.1200/JCO.2012.45.2524.; Ho V.K.Y., Deijen C.L., Hemmes B., et al. Trends in epidemiology and primary treatment of anal squamous cell carcinoma in the Netherlands (1990-2021) // Int J Cancer. 2024. Vol. 154, №9. Р. 1569–1578. doi:10.1002/ijc.34811.; Bucchi L., Pizzato M., Rosso S., et al. New Insights into the Epidemiology of Vulvar Cancer: Systematic Literature Review for an Update of Incidence and Risk Factors // Cancers (Basel). 2022. Vol. 14, № 2. Р. 389. doi:10.3390/cancers14020389.; Oonk M.H.M., Planchamp F., Baldwin P., et al. European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023 // Int J Gynecol Cancer. 2023. Vol. 33, №7. Р. 1023–1043. doi:10.1136/ijgc-2023-004486.; Judson P.L., Habermann E.B., Baxter N.N., et al. Trends in the incidence of invasive and in situ vulvar carcinoma // Obstetrics and Gynecology. 2006. Vol. 107, №5. Р. 1018–1022. doi:10.1097/01.AOG.0000210268.57527.a1.; Gadducci A., Fabrini M.G., Lanfredini N., et al. Squamous Cell Carcinoma of the Vagina: Natural History, Treatment Modalities and Prognostic Factors // Crit Rev Oncol Hematol. 2015. Vol. 93. Р. 211–224. doi:10.1016/j.critrevonc.2014.09.002.; IARC, Urinary and Male Genital Tumours. WHO Classification of Tumours, 5th Edn. Vol. 8. 2022. Доступно по: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Urinary-And-Male-Genital-Tumours-2022. Ссылка активна на 18 апреля 2024.; Муравьева Е. С., Богданова Н. А. Опыт диагностики и лечения эритроплазии Кейра // Тверской медицинский журнал. 2023. № 6. С. 25–28.; Giona S., Barber N., Ali A., editors. The Epidemiology of Penile Cancer // Urologic Cancers [Internet]. Brisbane (AU): Exon Publications. 2022. Chapter 11. doi:10.36255/exonpublications- urologic-cancers-epidemiology-penile-cancer.; Лялина Л.В., Холопов Д.В., Хижа В.В., и др. Гендерные особенности злокачественных новообразований, ассоциированных с вирусом папилломы человека, в Санкт-Петербурге // Пермский медицинский журнал. 2022. Т. 39, №4. С. 144–154.; Лялина Л.В., Холопов Д.В., Язенок А.В., и др. Клинико-эпидемиологическая характеристика злокачественных новообразований, ассоциированных с вирусом папилломы человека, в регионах Северо-Запада России // Журнал микробиологии, эпидемиологии и иммунобиологии. 2023. Т. 100, №1. С. 52–64.; Макарова Е.В., Сеньчукова М.А. Рак шейки матки в Оренбургской области и Российской Федерации за 2007-2016 годы // Оренбургский медицинский вестник. 2018. Т. 6, №4(24). С. 20–30.; EAU Guidelines // Edn. presented at the EAU Annual Congress Paris. 2024. Доступно по: https://uroweb.org/guidelines/penile-cancer/chapter/citation-information. Ссылка активна на 2 мая 2024.; Siegel R.L., Giaquinto A.N., Jemal A. Cancer statistics, 2024 // CA Cancer J Clin. 2024. Vol. 74, №1. Р. 12‐49. doi:10.3322/caac.21820.; Mix J.M., Van Dyne E.A., Saraiya M., et al. Assessing Impact of HPV Vaccination on Cervical Cancer Incidence among Women Aged 15-29 Years in the United States, 1999-2017: An Ecologic Study // Cancer Epidemiol Biomarkers Prev. 2021. Vol. 30, №1. Р. 30–37. doi:10.1158/1055-9965.EPI-20-0846.; Baandrup L., Maltesen T., Dehlendorff C., et al. Human papillomavirus vaccination and anal high-grade precancerous lesions and cancer—a real-world effectiveness study // JNCI: Journal of the National Cancer Institute. 2024. Vol. 116, №2. P. 283–287. doi:10.1093/jnci/djad189.; Elst L., Albersen M. HPV Vaccination: Does It Have a Role in Preventing Penile Cancer and Other Preneoplastic Lesions? // Semin Oncol Nurs. 2022. Vol. 38, №3. Р. 151284. doi:10.1016/j.soncn.2022.151284.; https://www.epidemvac.ru/jour/article/view/2116

  7. 7
    Academic Journal

    Συνεισφορές: The authors are grateful to the staff of intensive care units and epidemiologists from 50 medical organizations in 27 subjects of all federal districts of the Russian Federation for their assistance in conducting the research, Авторы благодарят сотрудников отделений реанимации и интенсивной терапии, врачей-эпидемиологов из 50 медицинских организаций 27 субъектов всех федеральных округов Российской Федерации за содействие в проведении исследований.

    Πηγή: Epidemiology and Vaccinal Prevention; Том 24, № 1 (2025); 4-9 ; Эпидемиология и Вакцинопрофилактика; Том 24, № 1 (2025); 4-9 ; 2619-0494 ; 2073-3046

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.epidemvac.ru/jour/article/view/2163/1093; Stewart S, Robertson C, Pan J, Kennedy S, et al. Epidemiology of healthcare-associated infection reported from a hospital-wide incidence study: considerations for infection prevention and control planning. J Hosp Infect. 2021;114:10–22.; Ali S, Birhane M, Bekele S, et al. Healthcare associated infection and its risk factors among patients admitted to a tertiary hospital in Ethiopia: longitudinal study. Antimicrob Resist Infect Control. 2018;7:1–9.; Nasiri, N., Sharifi, A., Ghasemzadeh, I., et al. Incidence, accuracy, and barriers of diagnosing healthcare-associated infections: a case study in southeast Iran. BMC Infect Dis 23, 171 (2023). https://doi.org/10.1186/s12879-023-08122-1; Munier-Marion E, Bénet T, Vanhems P. Definition of healthcare-associated influenza: A review and results from an international survey. Influenza Other Respir Viruses. 2017;11(5):367–371. doi: https://doi.org/10.1111/irv.12460; Huerta-Gutiérrez R, Braga L, Camacho-Ortiz A, et al. One-day point prevalence of healthcare-associated infections and antimicrobial use in four countries in Latin America. Int J Infect Dis. 2019;86:157–166. doi: https://doi.org/10.1016/j.ijid.2019.06.016; Metsini A, Vazquez M, Sommerstein R, et al. The Swissnoso Network. Point prevalence of healthcare-associated infections and antibiotic use in three large Swiss acute-care hospitals. Swiss Med Wkly. 2018;148:w14617. doi: https://doi.org/10.4414/smw.2018.14617; Брико Н. И., Брусина Е. Б., Зуева Л. П. и др. Госпитальный штамм — непознанная реальность. Эпидемиология и вакцинопрофилактика. 2013; № 1 (68), С. 30–35.; Surveillance of health care-associated infections at national and facility levels: practical handbook. ISBN 978-92-4-010145-6 (electronic version); ISBN 978-92-4-010146- 3 (print version)/ World Health Organization, 2024.; Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Antimicrobial Resistance Collaborators †. The Lancet. Vol. 399, ISSUE 10325, P629-655, FEBRUARY 12, 2022. https://doi.org/10.1016/S0140-6736(21)02724-0; Serra-Burriel M, Keys M, Campillo-Artero C, et al. Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis. PLoS One. 2020 Jan 10;15(1):e0227139. doi:10.1371/journal.pone.0227139. PMID: 31923281; PMCID: PMC6953842; Pulingam T, Parumasivam T, Gazzali AM, et al. Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome. Eur J Pharm Sci. 2022 Mar 1;170:106103. doi:10.1016/j.ejps.2021.106103. Epub 2021 Dec 20. PMID: 34936936.; Butler MS, Gigante V, Sati H, et al. Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0199121. doi:10.1128/AAC.01991-21. Epub 2022 Jan 10. PMID: 35007139; PMCID: PMC8923189.; Khokhlova, O.E., Vladimirov, I.V., Kozlov, R.S., et al. Molecular-Genetic Mechanisms of Resistance to Antibiotic of the Pathogens in Patients with Thermal Burns and Infection. Mol. Genet. Microbiol. Virol. 37, 187–193 (2022). https://doi.org/10.3103/S0891416822040024.; https://www.epidemvac.ru/jour/article/view/2163

  8. 8
    Academic Journal

    Πηγή: Epidemiology and Vaccinal Prevention; Том 23, № 6 (2024); 4-12 ; Эпидемиология и Вакцинопрофилактика; Том 23, № 6 (2024); 4-12 ; 2619-0494 ; 2073-3046

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.epidemvac.ru/jour/article/view/2114/1077; Вакцины и иммунопрофилактика в современном мире: Руководство для врачей. Л. С. Намазова-Баранова, Н. И. Брико, И.В. Фельдблюм, ред. Москва: «Педиатръ», 2021, – 648с.; Таточенко В. К., Озерецковский Н. А. Иммунопрофилактика -2020: справочник, 14-е издание, расширенное. 2020:100.; Вакцинопрофилактика у детей и взрослых: руководство для врачей. Фельдблюм И. В., Зуева Л. П., Асланов Б. И., ред. Санкт-Петербург: ГЭОТАР-Медиа, 2023. – 288с.; Vaccine schedules in all countries of the European Union. Доступно на: https://vaccine-schedule.ecdc.europa.eu; Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, United States, 2021. Available from: https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf; Der Impfkalender enthält die empfohlenen Standardimpfungen für Säuglinge, Kinder, Jugendliche und Erwachsene. Erscheinungsdatum 20. August 2020. Доступно на: https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Aktuelles/Impfkalender.pdf?__blob=publicationFile; Immunization against infectious disease. Green book. Public Health England. Last updated 27 November 2020. Доступно на: https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book#the-green-book; Il calendario vaccinale del Piano Nazionale di Prevenzione Vaccinale 2017–2019. Доступно на: https://www.salute.gov.it/imgs/C_17_pagineAree_4829_listaFile_itemName_0_file.pdf; Calendrier des vaccinations et recommandations vaccinales 2021. Доступно на: https://solidarites-sante.gouv.fr/IMG/pdf/calendrier_vaccinal_090721.pdf; Immunisation Schedule Queensland. 2020. Доступно наДоступно на: https://www.health.qld.gov.au/__data/assets/pdf_file/0032/989114/qld-immunisation-schedulechildren.pdf.; Намазова-Баранова Л. С., Федосеенко М. В., Баранов А. А. Новые горизонты национального календаря профилактических прививок. Вопросы современной педиатрии. 2019. Т. 18. № 1. С. 13–30.; Вакцинопрофилактика работающего населения: Руководство для врачей. Бухтияров И. В., Брико Н. И., ред. Москва: ООО «Издательство «Медицинское информационное агентство», 2019. – 192с.; Фельдблюм И. В. Риск-менеджмент в сфере вакцинопрофилактики как одно из направлений обеспечения эпидемиологической и биологической безопасности. Эпидемиология и Вакцинопрофилактика. 2018; 17 (5): 25–30 DOI:10.31631/2073-3046-2018-17-5-25-30.; https://www.epidemvac.ru/jour/article/view/2114

  9. 9
    Academic Journal

    Πηγή: Epidemiology and Vaccinal Prevention; Том 23, № 6 (2024); 54-60 ; Эпидемиология и Вакцинопрофилактика; Том 23, № 6 (2024); 54-60 ; 2619-0494 ; 2073-3046

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.epidemvac.ru/jour/article/view/2120/1082; Khan M. T., Van Dijl J. M., Harmsen H. J. M. Antioxidants keep the potentially probiotic but highly oxygen-sensitive human gut bacterium Faecalibacterium prausnitzii alive at ambient air. PLoS One, vol. 9, no. 5, 2014, doi:10.1371/journal.pone.0096097.; Goldin B. R. Health benefits of probiotics. Nutr. 1998 Oct;80(4):S203-7. PMID: 9924285.; Vyas U. and Ranganathan N. Probiotics, prebiotics, and synbiotics: Gut and beyond. Gastroenterology Research and Practice. 2012. doi:10.1155/2012/872716.; Gibson G. R. and Roberfroid M. B. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. Journal of Nutrition, vol. 125. no. 6. 1995. doi:10.1093/jn/125.6.1401.; Gibson G. R., Beatty E. R., Wang X., et al. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology, vol. 108, no. 4, 1995. doi:10.1016/0016-5085(95)90192-2.; Kolida S. and Gibson G. R. Synbiotics in health and disease. Annu Rev Food Sci Technol, vol. 2, 2011. doi:10.1146/annurev-food-022510-133739.; Mortensen P. B., Clausen M. R. Short-chain fatty acids in the human colon: Relation to gastrointestinal health and disease. Scandinavian Journal of Gastroenterology, Supplement, vol. 31, no. 216. 1996. doi:10.3109/00365529609094568.; Hague A., Singh B., Paraskeva C. Butyrate acts as a survival factor for colonic epithelial cells: Further fuel for the in vivo versus in vitro debate. Gastroenterology, vol. 112, no. 3, 1997, doi:10.1053/gast.1997.v112.agast971036.; Sakata T. Stimulatory effect of short-chain fatty acids on epithelial cell proliferation in the rat intestine: a possible explanation for trophic effects of fermentable fibre, gut microbes and luminal trophic factors. British Journal of Nutrition, vol. 58, no. 1, 1987, doi:10.1079/bjn19870073.; Shimotoyodome A., Meguro S., Hase T., et al. Decreased colonic mucus in rats with loperamide-induced constipation. Comparative Biochemistry and Physiology - A Molecular and Integrative Physiology, vol. 126, no. 2, 2000, doi:10.1016/S1095-6433(00)00194-X.; Martín R., Miquel S., Benevides L., et al., Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: A step forward in the use of F. prausnitzii as a next-generation probiotic. Front Microbiol, vol. 8, no. JUN, 2017, doi:10.3389/fmicb.2017.01226.; World Gastroenterology Organisation Global Guidelines Probiotics and prebiotics, 2017.; Bircher L., Geirnaert A., Hammes F., et al. Effect of cryopreservation and lyophilization on viability and growth of strict anaerobic human gut microbes. Microb Biotechnol, vol. 11, no. 4, 2018, doi:10.1111/1751-7915.13265.; Malik K. A. Cryopreservation of bacteria with special reference to anaerobes. World J Microbiol Biotechnol, vol. 7, no. 6, 1991, doi:10.1007/BF00452850.; Meryman H. T. Cryopreservation of living cells: Principles and practice. Transfusion, vol. 47, no. 5. 2007. doi:10.1111/j.1537-2995.2007.01212.x.; Broeckx G., Vandenheuvel D., Claes I. J. J., et al. Drying techniques of probiotic bacteria as an important step towards the development of novel pharmabiotics. International Journal of Pharmaceutics, vol. 505, no. 1–2. 2016. doi:10.1016/j.ijpharm.2016.04.002.; Heylen K., Hoefman S., Vekeman B., et al. Safeguarding bacterial resources promotes biotechnological innovation. Applied Microbiology and Biotechnology, vol. 94, no. 3. 2012. doi:10.1007/s00253-011-3797-y.; Bellali S., Bou Khalil J., Fontanini A., et al. A new protectant medium preserving bacterial viability after freeze drying. Microbiol Res, vol. 236, 2020, doi:10.1016/j.micres.2020.126454.; de Valdez G. F., de Giori G. S., de Ruiz Holgado A. P., et al. Comparative study of the efficiency of some additives in protecting lactic acid bacteria against freeze-drying. Cryobiology, vol. 20, no. 5, 1983, doi:10.1016/0011-2240(83)90044-5.; Khan M. T., Duncan S. H., Stams A. J. M., et al. The gut anaerobe Faecalibacterium prausnitzii uses an extracellular electron shuttle to grow at oxic-anoxic interphases. ISME Journal, vol. 6, no. 8, 2012, doi:10.1038/ismej.2012.5.; Neyrinck A.M., Van Hée V.F., Piront N. et al. Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satietogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice. Nutr Diabetes, vol. 2, no. JANUARY, 2012, doi:10.1038/nutd.2011.24.; Neyrinck A.M., Possemiers S., Druart C., et al. Prebiotic effects of wheat Arabinoxylan related to the increase in bifidobacteria, roseburia and bacteroides/prevotella in dietinduced obese mice. PLoS One, vol. 6, no. 6, 2011, doi:10.1371/journal.pone.0020944.; Gänzle M. G. and Follador R. Metabolism of oligosaccharides and starch in lactobacilli: A review. Frontiers in Microbiology, vol. 3, no. SEP. 2012. doi:10.3389/fmicb.2012.00340.; Baumann D. Preservation of lactic cultures., 1964.; Fowler A. and Toner M. Cryo-injury and biopreservation. Annals of the New York Academy of Sciences, vol. 1066. 2006. doi:10.1196/annals.1363.010.; Leslie S. B., Israeli E., Lighthart B., et al. Trehalose and sucrose protect both membranes and proteins in intact bacteria during. Appl Environ Microbiol, vol. 61, no. 10, 1995, doi:10.1128/aem.61.10.3592-3597.1995.; Crowe J. H., Carpenter J. F., Crowe L. M. The role of vitrification in anhydrobiosis. Annual Review of Physiology, vol. 60. 1998. doi:10.1146/annurev.physiol.60.1.73.; Бембеева Б.О., Исаева Е.Л., Муравьева В.В. и др. Изучение кишечной микробиоты методом культуромики. Бактериология. 2024; 9(1): 58–62. DOI:10.20953/2500-1027-2024-1-58-62; https://www.epidemvac.ru/jour/article/view/2120

  10. 10
    Academic Journal

    Συνεισφορές: Мы хотели бы выразить нашу глубочайшую благодарность Министерству здравоохранения и охраны окружающей среды Республики Ирак, Иракскому совету по борьбе с раком, также каждому сотруднику каждого управления здравоохранения за их помощь в сборе данных. Мы благодарны Офису ВОЗ в Ираке за их техническую поддержку.

    Πηγή: Epidemiology and Vaccinal Prevention; Том 23, № 6 (2024); 34-46 ; Эпидемиология и Вакцинопрофилактика; Том 23, № 6 (2024); 34-46 ; 2619-0494 ; 2073-3046

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.epidemvac.ru/jour/article/view/2117/1080; Akinde OR, Phillips A A, Oguntunde, OA,and Afolayan OM (2015). Cancer mortality pattern in lagos university teaching hospital, lagos, Nigeria. Journal of cancer epidemiology, 2015, 842032. https://doi.org/10.1155/2015/842032; Akinyemiju, T (2018). Epigenetic Biomarkers in Cancer Epidemiology, Editor(s): Sabita Saldanha, In Translational Epigenetics, Epigenetic Mechanisms in Cancer, Academic Press, Volume 3, Pages 223-241; Ala’din A. 2nd edition. Baghdad: Ministry of Health; 2004. Dec, MD, FRCP, FFPH. Health in Iraq, the Current situation, our vision for the future and areas of work.; Al-Hashimi MM, Wang X.(2013). Comparing the cancer in Ninewa during three periods (1980-1990, 1991-2000, 2001-2010) using Poisson regression. J Res Med Sci. 18(12):1026-39. PMID: 24523792; PMCID: PMC3908522.; Alkhayatt, TN , Ali, ZA and Younis AH, (2021). The prevalence and pattern of leukemia among children in Mosul, Iraq. Teikyo medical journal 44, (06), 4653-4657.; Ervik M, Lam F, Ferlay J, et al.(2018). Cancer Today. Lyon, France: International Agency for Research on Cancer; 2016; Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. doi:10.1002/ijc.29210; Hussain AM, Lafta RK.(2021). Cancer Trends in Iraq 2000-2016. Oman Med J. 36(1):e219. doi:10.5001/omj.2021.18. PMID: 33552559; PMCID: PMC7847549.; International Organization for Migration (2019). Rural areas in Ninewa, International Zone, Baghdad/Iraq; M-Amen K, Abdullah OS, Amin AMS, et al.(2022). Cancer Incidence in the Kurdistan Region of Iraq: Results of a Seven-Year Cancer Registration in Erbil and Duhok Governorates. Asian Pac J Cancer Prev. 2022;23(2):601-615. Published 2022 Feb 1. doi:10.31557/APJCP.2022.23.2.601; Mattiuzzi C, Lippi G.(2019). Current Cancer Epidemiology. J Epidemiol Glob Health. 9(4):217-222. doi:10.2991/jegh.k.191008.001. PMID: 31854162; PMCID: PMC7310786.; Oliveria SA, Christos PJ, Berwick M.(1997). The role of epidemiology in cancer prevention. Proc Soc Exp Biol Med. 216(2):142-50. doi:10.3181/00379727-216-44164. PMID: 9349683.; Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F.(2020). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71(3):209-249. doi:10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.; WHO IARC.(2018). Estimated Cancer Incidence, Mortality and prevalence worldwide in 2012.fact sheet. Population fact sheet. 2018; Abulkhair O, Saadeddin A, Makram O, Gasmelseed A, Pasha T, Shehata H, Fakhoury HM.(2016). Vitamin D levels and breast cancer characteristics: Findings in patients from Saudi Arabia. J Steroid Biochem Mol Biol. 164:106-109. doi:10.1016/j.jsbmb.2015.11.003. Epub 2015 Nov 7. PMID: 26554935.; Al Balawi IA, Mir R, Abu-Duhier FM.(2018). Potential impact of vascular endothelial growth factor gene variation (−2578C> A) on breast cancer susceptibility in Saudi Arabia: a case-control study. Asian Pac J Cancer Prev. 19:1135–1143.; Alhuquail AJ, Alzahrani A, Almubarak H, et al. (2018).High prevalence of deliterous BRCA 1 and BRCA 2 germline mutations in arab breast and ovarian cancer patients. Breast Cancer Res Treat. 2018; Alqahtani WS, Almufareh NA, Domiaty DM, et al.(2020). Epidemiology of cancer in Saudi Arabia thru 2010-2019: a systematic review with constrained meta-analysis. AIMS Public Health. 7(3):679-696. Published 2020 Sep 11. doi:10.3934/publichealth.2020053; Alwan N, Kerr D.(2018). Cancer control in war-torn Iraq. Lancet Oncol. 19:291–2. doi:10.1016/S1470-2045(18)30135-9.; American cancer society (2020). Childhood Leukemia Causes, Risk Factors, and Prevention. Cancer.org. USA . https://www.cancer.org/cancer/types/leukemia-in-children/about/new-research. html; Cancer research UK (2023). Risks and causes of lung cancer. England and Wales; Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, et al.(2010). Expansion of cancer care and control in countries of low and middle income: A call to action. Lancet. 376:1186–93. doi:10.1016/S0140-6736(10)61152-X.; Fathi RA, Matti LY, Al-Salih HS, (2013).Godbold D. Environmental pollution by depleted uranium in Iraq with special reference to Mosul and possible effects on cancer and birth defect rates. Med Confl Surviv 29(1):7-25 . 10.1080/13623699.2013.765173; Fuliful FK, Ali RHA. and Ali,KHA (2021). A Statistical Analysis on the Incidence Rate of Lung Cancer in Karbala-Iraq during 2012-19, International Journal of Medical Research & Health Sciences, 10(3): 40-52; Habib SO, Hameed AL, Ajeel AN, Al-Hawaz MH, Al-Faddagh ZA, Nasr NG, et al. (2016).Epidemiology of breast cancer among females in Basrah. Asian Pac J Cancer Prev. 17:191–5. doi:10.7314/apjcp.2016.17.s3.191.; Hamadeh RR, Borgan SM, Sibai AM.(2017). Cancer research in the Arab world: A review of publications from seven countries between 2000–2013. Sultan Qaboos Univ Med J. 17:e147–54. doi:10.18295/squmj.2016.17.02.003; Hussain AM, Lafta RK.(2021). Cancer Trends in Iraq 2000-2016. Oman Med J. 36(1):e219. Published 2021 Jan 31. doi:10.5001/omj.2021.18; Ibrahim BA, Al-Humaish S and Al-Obaide MAI (2018). Tobacco Smoking, Lung Cancer, and Therapy in Iraq: Current Perspective. Front. Public Health 6:311. doi:10.3389/fpubh. 2018 .00311; Ifediora CO.(2019). Re-thinking breast and cervical cancer preventive campaigns in developing countries: the case for interventions at high schools. BMC Public Health. 3;19(1):503. doi:10.1186/s12889-019-6890-2. PMID: 31053073; PMCID: PMC6500011.; Kim, H. I., Lim, H., & Moon, A. (2018). Sex Differences in Cancer: Epidemiology, Genetics and Therapy. Biomolecules & therapeutics, 26(4), 335–342.; Mir R, Javid J, Al Balawi A, et al.(2018). A germline mutation in BRCA1 3’UTR variant predicts susceptibility to breast cancer in a Saudi Arabian population. Asian Pac J Cancer Prev. 19:859–866.; Mojsak D, Dębczyński M, Kuklińska B, et al.(2023). Impact of COVID-19 in Patients with Lung Cancer: A Descriptive Analysis. Int J Environ Res Public Health. 20(2):1583. Published 2023 Jan 15. doi:10.3390/ijerph20021583; Noronha V, Pinninti R, Patil VM, Joshi A, Prabhash K.(2016). Lung cancer in the Indian subcontinent. South Asian J Cancer. 5(3):95-103. doi:10.4103/2278-330X.187571; Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, et al.(2018). Global cancer control: Responding to the growing burden, rising costs and inequalities in access. ESMO Open. 3:e000285. doi:10.1136/esmoopen-2017-000285.; Pramesh, C.S., Badwe, R.A., Bhoo-Pathy, N. et al.( 2022).Priorities for cancer research in low- and middle-income countries: a global perspective. Nat Med 28, 649–657 .Apr;28(4):649-657.; Rahman S, Zayed H. (2018).Breast cancer in the GCC countries: A focus on BRCA1/2 and non-BRCA1/2 genes. Gene. 20;668:73-76. doi:10.1016/j.gene.2018.05.045. Epub 2018 May 17. PMID: 29777908.; Reyes R., López-Castro R., Auclin E., García T., Chourio M.J., Rodriguez A., López L., Laguna J.C., Lucena C., Molins L., et al(2021). MA03.08 Impact of COVID-19 Pandemic in the Diagnosis and Prognosis of Lung Cancer. J. Thorac. Oncol. 2021;16:S141.; Saeed, S. M.,(2009). Epstein-Barr virus in Hodgkin’s lymphoma-immunohistochemical case series study. Annals of the College of Medicine, Mosul, 2009. 35(2): p. 93-103.; Safiri, S., Noori, M., Nejadghaderi, S. et al. Burden of female breast cancer in the Middle East and North Africa region, 1990–2019. Arch Public Health 80, 168 (2022).; Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. doi:10.3322/caac.20138.; Wang Y, Freemantle N, Nazareth I, Hunt K. Gender differences in survival and the use of primary care prior to diagnosis of three cancers: An analysis of routinely collected UK general practice data. PLoS One. 2014;9:e101562. doi:10.1371/journal.pone.0101562.; Yue W, Wang JP, Li Y, et al. Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. Int J Cancer. 2010;127(8):1748-1757. doi:10.1002/ijc.25207; https://www.epidemvac.ru/jour/article/view/2117

  11. 11
    Academic Journal

    Πηγή: Epidemiology and Vaccinal Prevention; Том 23, № 6 (2024); 83-103 ; Эпидемиология и Вакцинопрофилактика; Том 23, № 6 (2024); 83-103 ; 2619-0494 ; 2073-3046

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.epidemvac.ru/jour/article/view/2125/1085; World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. [Internet] Available at: https://www.who.int/news/item/27–02–2017–who–publishes–list–of–bacteria–for–which–new–antibiotics–are–urgently–needed. Accessed: 5 Aug 2024.; Козлов Р. С., Кузьменков А. Ю., Виноградова А. Г. Антибиотикорезистентность как медицинская проблема. Вестник Российской академии наук. 2024. – Т. 94. – №1. – C. 11–18.; Falagas ME, Tansarli GS, Karageorgopoulos DE, et al. Deaths Attributable to Carbapenem–Resistant Enterobacteriaceae Infections. Emerging Infectious Diseases. 2014;20(7):1170–1175. doi:10.3201/eid2007.121004.; Otter JA, Burgess P, Davies F, et al. Counting the cost of an outbreak of carbapenemase–producing Enterobacteriaceae: an economic evaluation from a hospital perspective. Clin Microbiol Infect. 2017;23(3):188–196. doi:10.1016/j.cmi.2016.10.005; Cerceo E, Deitelzweig SB, Sherman BM, et al. Multidrug–Resistant Gram–Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microb Drug Resist. 2016;22(5):412–431. doi:10.1089/mdr.2015.0220; Devi LS, Broor S, Rautela RS, et al. Increasing Prevalence of Escherichia coli and Klebsiella pneumoniae Producing CTX–M–Type Extended–Spectrum Beta–Lactamase, Carbapenemase, and NDM–1 in Patients from a Rural Community with Community Acquired Infections: A 3–Year Study. Int J Appl Basic Med Res. 2020;10(3):156–163. doi:10.4103/ijabmr.IJABMR_360_19; Dickstein Y, Edelman R, Dror T, et al. Carbapenem–resistant Enterobacteriaceae colonization and infection in critically ill patients: a retrospective matched cohort comparison with non–carriers. J Hosp Infect. 2016;94(1):54–59. doi:10.1016/j.jhin.2016.05.018; McConville TH, Sullivan SB, Gomez–Simmonds A, et al. Carbapenem–resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90–day mortality in critically ill patients, an observational study. PLoS One. 2017;12(10):e0186195. doi:10.1371/journal.pone.0186195; Emmanuel Martinez A, Widmer A, Frei R, et al. ESBL–colonization at ICU admission: impact on subsequent infection, carbapenem-consumption, and outcome. Infect Control Hosp Epidemiol. 2019;40(4):408–413. doi:10.1017/ice.2019.5; Golzarri MF, Silva–Sánchez J, Cornejo–Juárez P, et al. Colonization by fecal extended–spectrum β-lactamase–producing Enterobacteriaceae and surgical site infections in patients with cancer undergoing gastrointestinal and gynecologic surgery. Am J Infect Control. 2019;47(8):916–921. doi:10.1016/j.ajic.2019.01.020; Massart N, Camus C, Benezit F, et al. Incidence and risk factors for acquired colonization and infection due to extended-spectrum beta–lactamase–producing Gram–negative bacilli: a retrospective analysis in three ICUs with low multidrug resistance rate. Eur J Clin Microbiol Infect Dis. 2020;39(5):889–895. doi:10.1007/s10096–019–03800–y; EUCAST. Clinical breakpoints – breakpoints and guidance. Archive of EUCAST tables and documents. [Internet]. Available at: https://www.eucast.org/ast_of_bacteria/previous_versions_of_documents. Accessed: 5 Aug 2024.; About Carbapenem–resistant Enterobacterales. [Internet]. Available at: https://www.cdc.gov/cre/about/index.html. Accessed: 5 Aug 2024.; Эйдельштейн М. В. Выявление β лактамаз расширенного спектра у грамотрицательных бактерий с помощью фенотипических методов. Клиническая Микробиология-Антимикробная Химиотерапия. 2001. Т.3, № 2. С. 183–189.; Hu Y, Qing Y, Chen J, et al. Prevalence, Risk Factors, and Molecular Epidemiology of Intestinal Carbapenem–Resistant Pseudomonas aeruginosa. Microbiol Spectr. 2021;9(3):e0134421. doi:10.1128/Spectrum.01344–21; Программа СКАТ (Стратегия контроля антимикробной терапии) при оказании стационарной медицинской помощи. Российские клинические рекомендации. С. В. Яковлев, Н. И. Брико, С. В. Сидоренко и др., ред. М.: Перо; 2018.; Yan L, Sun J, Xu X, Huang S. Epidemiology and risk factors of rectal colonization of carbapenemase–producing Enterobacteriaceae among high risk patients from ICU and HSCT wards in a university hospital. Antimicrob Resist Infect Control. 2020;9(1):155. doi:10.1186/s13756–020–00816–4; Kim HJ, Hyun J, Jeong HS, et al. Epidemiology and Risk Factors of Carbapenemase–Producing Enterobacteriaceae Acquisition and Colonization at a Korean Hospital over 1 Year. Antibiotics (Basel). 2023;12(4):759. doi:10.3390/antibiotics12040759; Rodríguez–Villodres Á, Martín–Gandul C, Peñalva G, et al. Prevalence and Risk Factors for Multidrug–Resistant Organisms Colonization in Long–Term Care Facilities Around the World: A Review. Antibiotics (Basel). 2021;10(6):680. doi:10.3390/antibiotics10060680; Kajova M, Khawaja T, Kantele A. European hospitals as source of multidrug–resistant bacteria: analysis of travellers screened in Finland after hospitalization abroad. J Travel Med. 2022;29(4):taac022. doi:10.1093/jtm/taac022; Heinemann M, Kleinjohann L, Rolling T, et al. Impact of antibiotic intake on the incidence of extended–spectrum β-lactamase-producing Enterobacterales in sub-Saharan Africa: results from a community based longitudinal study. Clin Microbiol Infect. 2023;29(3):340–345. doi:10.1016/j.cmi.2022.09.008; Bar Ilan M, Kjerulf A. Who should be screened for carbapenemase–producing Enterobacterales and when? A systematic review. J Hosp Infect. 2023;142:74–87. doi:10.1016/j.jhin.2023.09.018; Мониторинг антибиотикорезистентности с использованием платформы AMRcloud. Практическое руководство. Козлов Р. С., Виноградов А. Г., Кузьменков А. Ю. и др., ред. Смоленск: СГМУ; 2021.; Kelly AM, Mathema B, Larson EL. Carbapenem–resistant Enterobacteriaceae in the community: a scoping review. Int J Antimicrob Agents. 2017;50(2):127–134. doi:10.1016/j. ijantimicag.2017.03.012; Garrido A, Seral C, Gude MJ, et al. Characterization of plasmid–mediated β–lactamases in fecal colonizing patients in the hospital and community setting in Spain. Microb Drug Resist. 2014;20(4):301–304. doi:10.1089/mdr.2013.0109; Alexopoulou A, Papadopoulos N, Eliopoulos DG, et al. Increasing frequency of gram–positive cocci and gram–negative multidrug–resistant bacteria in spontaneous bacterial peritonitis. Liver Int. 2013;33(7):975–981. doi:10.1111/liv.12152; Lohiya A, Kant S, Kapil A, et al. Pattern of Antibiotic Resistance Among Community Derived Isolates of Enterobacteriaceae Using Urine Sample: A Study From Northern India. J Clin Diagn Res. 2015;9(7):LC15–LC19. doi:10.7860/JCDR/2015/14230.6254; Henderson J, Ciesielczuk H, Nelson SM, et al. Community prevalence of carbapenemase–producing organisms in East London. J Hosp Infect. 2019;103(2):142–146. doi:10.1016/j.jhin.2019.04.014; van den Bunt G, van Pelt W, Hidalgo L, et al. Prevalence, risk factors and genetic characterisation of extended–spectrum beta–lactamase and carbapenemase–producing Enterobacteriaceae (ESBL–E and CPE): a community–based cross–sectional study, the Netherlands, 2014 to 2016. Euro Surveill. 2019;24(41):1800594. doi:10.2807/1560–7917. ES.2019.24.41.1800594; Turnidge JD, Gottlieb T, Mitchell DH, et al. Australian Group on Antimicrobial Resistance Community–onset Gram–negative Surveillance Program annual report, 2010. Commun Dis Intell Q Rep. 2013;37(3):E219–E223.; Sheng WH, Badal RE, Hsueh PR; et al. Distribution of extended–spectrum β–lactamases, AmpC β–lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia–Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013;57(7):2981–2988. doi:10.1128/AAC.00971–12; Tang HJ, Hsieh CF, Chang PC, et al. Clinical Significance of Community– and Healthcare–Acquired Carbapenem–Resistant Enterobacteriaceae Isolates. PLoS One. 2016;11(3):e0151897. doi:10.1371/journal.pone.0151897; Miller BM, Johnson SW. Demographic and infection characteristics of patients with carbapenem–resistant Enterobacteriaceae in a community hospital: Development of a bedside clinical score for risk assessment. Am J Infect Control. 2016;44(2):134–137. doi:10.1016/j.ajic.2015.09.006; Guh AY, Bulens SN, Mu Y, et al. Epidemiology of Carbapenem–Resistant Enterobacteriaceae in 7 US Communities, 2012–2013. JAMA. 2015;314(14):1479–1487. doi:10.1001/jama.2015.12480; Thaden JT, Lewis SS, Hazen KC, et al. Rising rates of carbapenem–resistant enterobacteriaceae in community hospitals: a mixed–methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol. 2014;35(8):978–983. doi:10.1086/677157; Brennan BM, Coyle JR, Marchaim D, et al. Statewide surveillance of carbapenem–resistant enterobacteriaceae in Michigan. Infect Control Hosp Epidemiol. 2014;35(4):342– 349. doi:10.1086/675611; Li K, Jiang S, Fu H, et al. Risk Factors and Prognosis of Carbapenem–Resistant Organism Colonization and Infection in Acute Cholangitis. Infect Drug Resist. 2022;15:7777–7787. doi:10.2147/IDR.S398581; Tian F, Li Y, Wang Y, et al. Risk factors and molecular epidemiology of fecal carriage of carbapenem resistant Enterobacteriaceae in patients with liver disease. Ann Clin Microbiol Antimicrob. 2023;22(1):10. doi:10.1186/s12941–023–00560–8; Satlin MJ, Chen L, Gomez–Simmonds A, et al. Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime–Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem–Resistant Enterobacterales. Clin Infect Dis. 2022;75(12):2066–2075. doi:10.1093/cid/ciac354; Recio R, Villa J, Viedma E, et al. Bacteraemia due to extensively drug–resistant Pseudomonas aeruginosa sequence type 235 high–risk clone: Facing the perfect storm. Int J Antimicrob Agents. 2018;52(2):172–179. doi:10.1016/j.ijantimicag.2018.03.018; Baier C, Beck M, Panagiota V, et al. Infection control management and surveillance of carbapenem–resistant Gram–negative bacteria in hematopoietic stem cell recipients. Antimicrob Resist Infect Control. 2019;8:160. doi:10.1186/s13756–019–0606–3; Cattaneo C, Di Blasi R, Skert C, et al. Bloodstream infections in haematological cancer patients colonized by multidrug–resistant bacteria. Ann Hematol. 2018;97(9):1717–1726. doi:10.1007/s00277–018–3341–6; Jiang Y, Ding Y, Wei Y, Jian C, Liu J, Zeng Z. Carbapenem–resistant Acinetobacter baumannii: A challenge in the intensive care unit. Front Microbiol. 2022;13:1045206. doi:10.3389/fmicb.2022.1045206; Hu H, Wang Y, Sun J, et al. Risk factors and molecular epidemiology of intestinal colonization by carbapenem–resistant Gram–negative bacteria in patients with hematological diseases: a multicenter case‒control study. Microbiol Spectr. 2024;12(7):e0429923. doi:10.1128/spectrum.04299–23; Кузьменков А. Ю., Виноградова А. Г., Трушин И. В. и др. AMRmap – система мониторинга антибиотикорезистентности в России. Клиническая микробиология и антимикробная химиотерапия. 2021. Т.23, №2. С.198–204.; Lautenbach E, Mosepele M, Smith RM, et al. Risk Factors for Community Colonization With Extended–Spectrum Cephalosporin–Resistant Enterobacterales (ESCrE) in Botswana: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study. Clin Infect Dis. 2023;77(Suppl 1):S89–S96. doi:10.1093/cid/ciad259; Caudell MA, Castillo C, Santos LF, et al. Risk factors for colonization with extended–spectrum cephalosporin–resistant and carbapenem–resistant Enterobacterales among hospitalized patients in Guatemala: An Antibiotic Resistance in Communities and Hospitals (ARCH) study. IJID Reg. 2024;11:100361. doi:10.1016/j.ijregi.2024.100361; Moghnieh R, Abdallah D, Jadayel M, et al. Epidemiology, risk factors, and prediction score of carbapenem resistance among inpatients colonized or infected with 3rd generation cephalosporin resistant Enterobacterales. Sci Rep. 2021;11(1):14757. doi:10.1038/s41598–021–94295–1; Park SH, Yi Y, Suh W, Ji SK, Han E, Shin S. The impact of enhanced screening for carbapenemase–producing Enterobacterales in an acute care hospital in South Korea. Antimicrob Resist Infect Control. 2023;12(1):62. doi:10.1186/s13756–023–01270–8; Клясова Г. А., Коробова А. Г., Фролова И. Н. и др. Детекция энтеробактерий с продукцией бета–лактамаз расширенного спектра у больных острыми миелоидными лейкозами и лимфомами при поступлении в стационар // Гематология и трансфузиология. 2016. Т.61, №1. С. 25–32.; Segagni Lusignani L, Presterl E, Zatorska B, et al. Infection control and risk factors for acquisition of carbapenemase producing enterobacteriaceae. A 5 year (2011–2016) case–control study. Antimicrob Resist Infect Control. 2020;9(1):18. doi:10.1186/s13756–019–0668–2; Salomão MC, Freire MP, Boszczowski I, et al. Increased Risk for Carbapenem–Resistant Enterobacteriaceae Colonization in Intensive Care Units after Hospitalization in Emergency Department. Emerg Infect Dis. 2020;26(6):1156–1163. doi:10.3201/eid2606.190965; Callejón Fernández M, Madueño Alonso A, Abreu Rodríguez R, et al. Risk factors for colonization by carbapenemase–producing bacteria in Spanish long–term care facilities: a multicentre point–prevalence study. Antimicrob Resist Infect Control. 2022;11(1):163. doi:10.1186/s13756–022–01200–0; Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011;62(6):591–599.; van Duin D, Paterson DL. Multidrug–Resistant Bacteria in the Community: An Update. Infect Dis Clin North Am. 2020;34(4):709–722. doi:10.1016/j.idc.2020.08.002; Shrestha R, Luterbach CL, Dai W, et al. Characteristics of community–acquired carbapenem–resistant Enterobacterales. J Antimicrob Chemother. 2022;77(10):2763–2771. doi:10.1093/jac/dkac239; Salomão MC, Guimarães T, Duailibi DF, et al. Carbapenem–resistant Enterobacteriaceae in patients admitted to the emergency department: prevalence, risk factors, and acquisition rate. J Hosp Infect. 2017;97(3):241–246. doi:10.1016/j.jhin.2017.08.012; Barbadoro P, Bencardino D, Carloni E, et al. Carriage of Carbapenem–Resistant Enterobacterales in Adult Patients Admitted to a University Hospital in Italy. Antibiotics (Basel). 2021;10(1):61. doi:10.3390/antibiotics10010061; van Loon K, Voor In ‘t Holt AF, Vos MC. A Systematic Review and Meta–analyses of the Clinical Epidemiology of Carbapenem–Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;62(1):e01730–17. doi:10.1128/AAC.01730–17; https://www.epidemvac.ru/jour/article/view/2125

  12. 12
    Academic Journal

    Συνεισφορές: The authors express their sincere gratitude for the help in conducting research: to the research doctors of Gomel State Medical University: BS Yaroshevich, OS Pershenkova, MN Mirga, to the research doctors of Gomel Regional Clinical Hospital: SG Berdnik, IA Krepchuk, DI Svirskaya, OL Palkovsky, FV Baginsky. Special thanks to TS Petrenko, Head of the laboratory at the Gomel Regional Clinical Hospital., Авторы выражают искреннюю благодарность за помощь в проведении исследований: врачам-исследователям Гомельского государственного медицинского университета: Божене Сергеевне Ярошевич, Ольге Сергеевне Першенковой, Марине Николаевне Мирге, врачам-исследователям Гомельской областной клинической больницы: Сергею Геннадьевичу Берднику, Ивану Александровичу Крепчуку, Дарье Игоревне Свирской, Олегу Леонидовичу Палковскому, Феликсу Владимировичу Багинскому. Отдельная благодарность заведующей лабораторией Гомельской областной клинической больницы Татьяне Станиславовне Петренко.

    Πηγή: Epidemiology and Vaccinal Prevention; Том 23, № 6 (2024); 61-72 ; Эпидемиология и Вакцинопрофилактика; Том 23, № 6 (2024); 61-72 ; 2619-0494 ; 2073-3046

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.epidemvac.ru/jour/article/view/2123/1083; Вакцины и иммунизация. Доступно на: https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1. Ссылка активна на 28.10.2024.; Bar-On Y.M., Goldberg Y., Mandel M., et al Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel // N. Engl. J. Med. 2021. Vol. 385, N15. P. 1393–1400.; Fontanet A., Cauchemez S. COVID-19 herd immunity: Where are we? // Nat. Rev. Immunol. 2020. Vol. 20. P. 583–584.; Стома И. О., Воропаев Е. В., Михайлова Е. И. и др. Оценка безопасности инактивированной цельновирионной бустер-вакцины против вируса SARSCoV-2 («БелКовидВак») у иммунизированных лиц от 18 до 60 лет (28-дневный период наблюдения). Эпидемиология и Вакцинопрофилактика. 2024. Т. 23, №3. C. 107–119.; Гасич Е. Л., Булда К. Ю., Дрозд А. М. и др. Применение современных технологий для молекулярно-эпидемиологического слежения за распространением возбудителя новой коронавирусной инфекции SARS-COV-2 и прогноза развития эпидемии COVID-19. Новости медико-биологических наук. 2021. Т. 21, № 4. С. 76–84.; Фельдблюм И. В., Девятков М. Ю., Репин Т. М. и др. Изменчивость вируса SARS-CoV-2 и восприимчивости населения в динамике развития эпидемического процесса. Эпидемиология и Вакцинопрофилактика. 2023. Т. 2, №5. C. 4–11.; Решение Совета Евразийской экономической комиссии № 79 от 3 ноября 2016 г. «Об утверждении Правил надлежащей клинической практики Евразийского экономического союза». Доступно на: https://pravo.by/document/?guid=3871&p0=F91600334. Ссылка активна на 20 октября 2024.; Kamińska D., Dęborska-Materkowska D., Kościelska-Kasprzak K., et al. Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences // Vaccines (Basel). 2022. Vol. 10, N7. P.1068.; Müller L., Kannenberg J., Biemann R., et al. Comparison of the measured values of quantitative SARS-CoV-2 spike antibody assays. J. Clin. Virol. 2022. Vol. 155. P. 105269.; Красько А. Г., Климович О. В., Семёнов С. Ф. и др.; Республиканский научно- практ. центр эпидемиологии и микробиологии. Метод нейтрализации вируса Sars-Cov-2 на культуре пермиссивных клеток для диагностики Covid-19. Инструкция по применению. Минск, 2023. Доступно на: https://www.belriem.by/images/docs/instruction_main/054-0623_18.12.2023.pdf. Ссылка активна на 28.10.2024; https://www.epidemvac.ru/jour/article/view/2123

  13. 13
    Academic Journal

    Πηγή: Epidemiology and Vaccinal Prevention; Том 24, № 1 (2025); 42-49 ; Эпидемиология и Вакцинопрофилактика; Том 24, № 1 (2025); 42-49 ; 2619-0494 ; 2073-3046

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.epidemvac.ru/jour/article/view/2167/1097; Ballester-Ferré M.P., Martínez F., Garcia-Gimeno N., et al. Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin. World Journal of Hepatology. 2017. Vol. 9, N3. P. 161–166. doi:10.4254/wjh.v9.i3.161; Tuberculosis in Russian Federation [Internet]. World Health Organization. Доступно на: https:. worldhealthorg.shinyapps.io/TBrief/?_inputs_&entity_type=%22country%22&iso2=%22RU%22&sidebarCollapsed=true&sidebarItemExpanded=null. Ссылка активна на 24 июня 2024.; Hepatitis C [Internet]. World Health Organization. Доступно на: https:. www.who.int/news-room/fact-sheets/detail/hepatitis-c. Ссылка активна на 24 июня 2024.; Ивашкин В. Т., Чуланов В. П., Мамонова Н. А. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Национального научного общества инфекционистов по диагностике и лечению хронического вирусного гепатита С. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023. Т. 33, № 1. С. 84–124. doi:10.22416/1382-4376-2023-33-1-84-124.; Соловьев Д. В. Эпидемиологические особенности вирусных гепатитов В и С у больных туберкулезом легких м и тактика их профилактики. Дис. канд. мед. наук. Москва; 2012.; Асратян А. А., Соловьев Д. В., Русакова Е. В. Современная эпидемическая ситуация по заболеваемости вирусными гепатитами и туберкулезом в Москве. Эпидемиология и Вакцинопрофилактика. 2015. Т. 14, № 3. С. 42–48. doi:10.31631/2073-3046-2015-14-3-42-48; Manca C., Tsenova L., Bergtold A., et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proceedings of the National Academy of Science USA. 2001. Vol. 98, N 10. P. 5752–5757. doi:10.1073/pnas.091096998; Kempker R.R., Alghamdi W.A., Al-Shaer M.H., et al. A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment. Antimicrobial Agents and Chemotherapt. 2019. Vol. 63, N12. P: e01215–e01219. doi:10.1128/aac.01215-19; Olaru I.D., Beliz Meier M., Mirzayev F., et al. Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and metaanalysis. eClinicalMedicine. 2023. Vol. 58. P. 101938. doi:10.1016/j.eclinm.2023.101938; Kim W.S., Lee S.S., Lee C.M., et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infectious Diseases. 2016. Vol. 16. P. 50. doi:10.1186/s12879-016-1344-2; Ungo J.R., Jones D., Ashkin D., et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. American Journal of Respiratory and Critical Care Medicine. 1998. Vol. 157, N6, Pt 1. P. 1871–1876. doi:10.1164/ajrccm.157.6.9711039; Lin S.Y., Chen T.C., Lu P.L., et al. Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan. BMC Infectious Diseases. 2014. Vol.14, P. 705. doi:10.1186/s12879-014-0705-y; Zein N.N. Clinical significance of hepatitis C virus genotypes . Clinical Microbiology Reviews. 2000. Vol. 13, N2. P. 223–235. doi:10.1128/CMR.13.2.223; Probst A., Dang T., Bochud M., et al. Role of Hepatitis C virus genotype 3 in liver fibrosis progression – a systematic review and meta-analysis. Journal of Viral Hepatitis. 2011. Vol. 18, N11. P. 745–759. doi:10.1111/j.1365-2893.2011.01481.x; Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998. Vol. 352, N9138. P. 1426–1432. doi:10.1016/s0140-6736(98)07124-4; Средневзвешенная стоимость схемы лечения гепатита С составляет 300—400 тыс. рублей. Фармацевтический Вестник. Доступно на: https: pharmvestnik.ru/content/news/Srednevzveshennaya-stoimost-shemy-lecheniya-gepatita-S-sostavlyaet-300-400-tys-rublei.html. Ссылка активна на 24 июня 2024.; Акимов И. А., Тимофеев Д. И., Мавзютов А. Р. и др. Выявление циркулирующей рекомбинантной формы RF1_2k/1b вируса гепатита С в сыворотке крови пациентов методом ОТ-ПЦР в режиме реального времени. Клиническая лабораторная диагностика. 2021. Т. 66, №2. С. 122–128. doi:10.51620/0869-2084-2021-66-122-128; Esteban J.I., Sauleda S., Quer J. The changing epidemiology of hepatitis C virus infection in Europe. Journal of Hepatology. 2008. Vol. 48, N1. P. 148–162. doi:10.1016/j.jhep.2007.07.033; Pimenov N., Kostyushev D., Komarova S., et al. Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia. Pathogens. 2022 Vol. 11, N12. P. 1482. doi:10.3390/pathogens11121482; Kichatova V.S., Kyuregyan K.K., Soboleva N.V., et al. Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context. Journal of Immunology Research. 2018. Vol. 2018. P. 7685371. doi:10.1155/2018/7685371; Chida T., Watanabe S., Ohta K., et al. Impact of amino acid substitutions in hepatitis C virus core region on the severe oxidative stress. Free Radical Biology and Medicine. 2024. Vol. 212. P.199–206. doi:10.1016/j.freeradbiomed.2023.12.014; https://www.epidemvac.ru/jour/article/view/2167

  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20